HC Wainwright Predicts Shattuck Labs Q1 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Shattuck Labs in a report released on Thursday, March 27th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.40) per share for the quarter. HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Shattuck Labs' current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Shattuck Labs' Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($2.00) EPS.

STTK has been the subject of several other research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Shattuck Labs in a report on Thursday, March 27th. Leerink Partners assumed coverage on shares of Shattuck Labs in a research note on Monday, March 17th. They issued an "outperform" rating and a $4.00 price target for the company. Finally, Leerink Partnrs upgraded shares of Shattuck Labs to a "strong-buy" rating in a research note on Monday, March 17th. Four investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Shattuck Labs presently has a consensus rating of "Moderate Buy" and an average target price of $7.50.

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK traded down $0.17 on Monday, hitting $0.81. The company's stock had a trading volume of 97,539 shares, compared to its average volume of 376,261. The company has a market capitalization of $38.81 million, a price-to-earnings ratio of -0.53 and a beta of 1.66. Shattuck Labs has a 12 month low of $0.81 and a 12 month high of $11.76. The stock's 50-day moving average is $1.23 and its two-hundred day moving average is $1.41.

Remove Ads

Shattuck Labs (NASDAQ:STTK - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.01. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%.

Hedge Funds Weigh In On Shattuck Labs

Several large investors have recently made changes to their positions in the business. Zacks Investment Management acquired a new stake in Shattuck Labs during the fourth quarter valued at approximately $25,000. Virtu Financial LLC bought a new position in shares of Shattuck Labs in the fourth quarter valued at $30,000. Atom Investors LP acquired a new stake in shares of Shattuck Labs during the 3rd quarter valued at $35,000. Readystate Asset Management LP bought a new stake in shares of Shattuck Labs during the 3rd quarter worth $39,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Shattuck Labs in the 4th quarter worth $45,000. Institutional investors own 58.74% of the company's stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.